1 ml containing 5 mg drops butamiratu citrate; 10 ml of syrup contains 15 mg citrate butamiratu. Action: non-opioid antitussive centrally acting. Reduces the frequency and intensity of coughing, inhibiting the cough reflex at the level of the medulla oblongata. In addition, it decreases airway resistance, as evidenced by the rapid improvement of spirometric parameters and blood gas test results of blood. After oral administration, absorbed quickly and completely. It is metabolised by hydrolysis of the two metabolites (2-phenylbutyric dietyloaminoetoksyetanol), which also exhibit antitussive activity.Butamirate and its metabolites reach maximum concentration in the blood after about 1.5 h after administration (syrup). Metabolites, as butamirate unchanged to a large extent (about 95%), bind to plasma proteins. T 0.5 butamiratu is 6 h, 2-fenylomasłowego- 21 h and 5 h dietyloaminoetoksyetanolu-. The metabolites are excreted primarily in the urine. Indications: Treatment of acute cough of different etiology. Suppression of cough in the pre- and postoperative patients undergoing surgery and bronchoscopy. Contraindications: Hypersensitivity to ingredients. Pregnancy and lactation: The safety of the product during pregnancy and breast-feeding. Not recommended for use in the first trimester of pregnancy, in the second and third trimester of pregnancy used only in case of necessity. Avoid using the product during breastfeeding. Undesirable effects: Rarely observed: skin rashes, nausea, diarrhea, dizziness. These symptoms resolved after dose reduction or discontinuation of the preparation.Dosage: Oral. Drops - infants 7-12 m.ż .: 10 drops 4 times a day; Children 2-3 r.ż .: 15 drops four times a day; children over 3 r.ż .: 25 drops 4 times a day.